ArticleCureus2025
Unraveling the Overlapping Spectrum of Hereditary Neuropathies: Clinical and Genetic Insights From the UAE.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary sensory and motor neuropathies (HSMNs) remain underreported in the United Arab Emirates (UAE), where overlapping clinical features often delay diagnosis. These case series describe the clinical and genetic diversity of HSMNs through the evaluation of five Emirati male patients, aged 18-47 years diagnosed with Charcot-Marie-Tooth disease (CMT) and Hereditary Neuropathy with Liability to Pressure Palsies (HNPP), focusing on phenotypic variability and diagnostic challenges. Patients presented with a range of symptoms, from episodic focal neuropathies to progressive distal weakness and motor impairment. Clinical assessment, electrophysiological studies and genetic testing revealed a number of underlying mutations, including PMP22 duplications (CMT1A), PMP22 deletions (HNPP), GJB1 mutation (CMTX), and SH3TC2 mutation (CMT4C). The CMT4C case exhibited early-onset scoliosis and severe neuropathy, while others exhibited milder or episodic symptoms. One HNPP patient with a PMP22 deletion exhibited progressive deficits resembling CMT, emphasizing the phenotypic overlap between HNPP and CMT. Electrophysiological studies showed demyelinating polyneuropathy with varying degrees of axonal involvement. These findings highlight the challenges posed by HSMNs and the importance of integrating clinical assessment, electrophysiological evaluation, and comprehensive genetic testing for accurate diagnosis and management. This multidisciplinary approach is critical for distinguishing between CMT and HNPP, offering clarity in cases with atypical or overlapping phenotypes and supporting the need for personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.